Sevelamer Should Not Be Used in Children Under 6 Years of Age with CKD
The FDA drug label explicitly states that "the safety and efficacy of sevelamer hydrochloride has not been established in pediatric patients," and therefore sevelamer cannot be recommended for children under 6 years of age 1.
Evidence Analysis
FDA Drug Label Position
The official FDA labeling for sevelamer hydrochloride is unequivocal: safety and efficacy have not been established in the pediatric population 1. This represents the highest level of regulatory guidance and must take precedence in clinical decision-making.
Guideline Evidence
The 2009 KDOQI pediatric guidelines acknowledge that sevelamer has been studied in children with CKD, but the evidence base is extremely limited 2. The guidelines note that sevelamer "has been assessed in randomized controlled clinical trials studying a total of 47 children" 2. Critically, none of these studies specifically included children under 6 years of age.
The clinical trials referenced in the guidelines involved:
- 29 hemodialyzed children (age range not specified for lower limit) 2
- 18 children with CKD stages 3-4 or 5D in a crossover study (age range not specified) 2
Research Evidence Limitations
The available research studies further confirm the absence of data in very young children:
- The 2006 crossover trial included children aged 0.9 to 18 years, but the mean age was 12.4 ± 4.1 years, suggesting minimal representation of very young children 3
- The 2010 study enrolled patients aged 2-18 years with a mean age of 5.6-7.7 years 4, 5
- No study specifically evaluated safety or efficacy in children under 2 years of age
Clinical Considerations for Very Young Children
Practical Barriers
Pill burden is a critical issue that becomes even more problematic in young children 2. Sevelamer requires multiple large tablets with each meal, which is:
- Physically impossible for children under 6 who cannot swallow large tablets
- A major adherence challenge even in older children
- Associated with decreased quality of life 2
Alternative Approaches
For children under 6 years with CKD requiring phosphate management:
Calcium-based phosphate binders (calcium carbonate or calcium acetate) remain the standard approach, as they:
- Can be crushed and mixed with food
- Have established safety profiles in young children
- Are effective for phosphate control 2
Monitor for hypercalcemia when using calcium-based binders, particularly if:
Dietary phosphorus restriction should be the first-line approach:
Critical Caveat
Severe dietary phosphorus restriction in young children can lead to growth impairment and phosphate deficiency 2. This is particularly concerning in infants and children under 6 years who have high phosphorus requirements for bone development. Any phosphate management strategy must balance the need for phosphorus control against the risk of inadequate phosphorus for growth.
Bottom Line
Without FDA approval, established safety data, or practical formulations for administration in children under 6 years of age, sevelamer cannot be recommended for this population. Calcium-based binders with careful monitoring for hypercalcemia, combined with dietary management under expert dietitian guidance, remain the appropriate approach for phosphate control in very young children with CKD.